Press releases

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi^® Cell Avidity Analyzer

In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…

j.yeh26 May 2021

Press releases

LUMICKS to return COVID-related relief funding to Dutch and US governments

LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announces that it has made the decision to return the COVID-related relief funding it received in both the Netherlands and the United States. During 2020, LUMICKS received a total…

j.yeh18 May 2021

Press releases

LUMICKS Raises $93 Million in Series D Financing

Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors. Amsterdam, the Netherlands – April 16, 2021 – LUMICKS,…

j.yeh15 April 2021

Press releases

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

In their quest of creating safe and effective immunotherapy cancer treatments, LUMICKS and LAVA Therapeutics joined forces. The partnership aims to evaluate the efficacy of various tumor-specific γδ T-cell engagers based on the resulting binding strengths (cell avidity) between T cells and tumors, measured with LUMICKS newly installed z-Movi® Cell…

j.yeh4 December 2020

Press releases

LUMICKS enters strategic collaboration with Leucid Bio to evaluate next-generation pCARs

LUMICKS is pleased to announce a collaboration agreement with clinical-stage biotech company Leucid Bio, which seeks to utilize LUMICKS’ z-Movi® Cell Avidity Analyzer to accelerate entry of immunotherapeutic candidates into clinical trials. The goal of the partnership is to evaluate the efficacy of Leucid Bio’s next-generation CAR T-cells using the…

j.yeh30 October 2020

Press releases

Introduction of LUMICKS consumables and script-sharing platform to facilitate faster, easier, and more reproducible Dynamic Single-Molecule analysis

In a move to broadly unlock Dynamic Single-Molecule (DSM) analysis, LUMICKS simultaneously launched two major initiatives: a new business line for reagents, biochemistry kits, and services, as well as its Harbor platform for sharing of DSM scripts. These new resources dramatically simplify the experimental workflow and make DSM analysis accessible…

j.yeh2 October 2020

Press releases

LUMICKS opens new branch office in Beijing to serve the Asian market

LUMICKS is proud to announce the opening of its branch office in Beijing, China. As LUMICKS continues to expand within the rapidly developing life sciences and immuno-oncology market in the Asia Pacific Region (APR), the new office will allow to better serve the market opportunity, support local customers, and collaborate…

j.yeh28 August 2020

Press releases

LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy

We are excited to announce that LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population…

j.yeh30 July 2020

Press releases

Minister van Engelshoven Inaugurates New LUMICKS Headquarters in Amsterdam

On September 16 we celebrated the grand opening of its new headquarters in Amsterdam. Ingrid van Engelshoven, Dutch minister of Education, Culture and Science (OCW) performed the opening ceremony by cutting a DNA molecule using a laser beam. The new headquarters of LUMICKS are in an old bicycle factory, situated…

j.yeh16 September 2019

Department of Biochemistry, University of Cambridge

Press releases

New Centre of Excellence in Dynamic Single-Molecule Analysis for Accelerated Drug Discovery in collaboration with AstraZeneca and the University of Cambridge

The center will be based around LUMICKS’ C-Trap® optical tweezers–fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs.

j.yeh27 June 2018

Join our newsletter

First Name

Last Name

E-mail address *

Country

Get exclusive news on the latest publications, product developments, events and breakthrough science.

Application of interest *

Dynamic single-molecule analysis

Cell avidity analysis

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Cookie	Duration	Description
Boxzilla	3 days	This cookie remembers if you have already closed a modal to make sure we don't show you the same information twice.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_57399829_1	1 minute	Set by Google to distinguish users.
_gcl_au	3 months	Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Google Analytics Universal	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
pardot	past	The pardot cookie is set while the visitor is logged in as a Pardot user. The cookie indicates an active session and is not used for tracking.
Pardot visitor	1 year	No description
Pardot visitor hashed	1 year	The Pardot cookie to link visitors to prospects

Cookie	Duration	Description
Cience		Tracking performance of Cience ads
test_cookie	15 minutes	The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies.

Applications

Products

Science

Company

Regensburg Center for Interventional Immunology adopts LUMICKS’ z-Movi^® Cell Avidity Analyzer

LUMICKS to return COVID-related relief funding to Dutch and US governments

LUMICKS Raises $93 Million in Series D Financing

LUMICKS enters collaboration with LAVA Therapeutics to characterize its tumor-specific γδ T-cell engagers

LUMICKS enters strategic collaboration with Leucid Bio to evaluate next-generation pCARs

Introduction of LUMICKS consumables and script-sharing platform to facilitate faster, easier, and more reproducible Dynamic Single-Molecule analysis

LUMICKS opens new branch office in Beijing to serve the Asian market

LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy

Minister van Engelshoven Inaugurates New LUMICKS Headquarters in Amsterdam

New Centre of Excellence in Dynamic Single-Molecule Analysis for Accelerated Drug Discovery in collaboration with AstraZeneca and the University of Cambridge

Recent Posts

Yearly Archive

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

Applications

Products

Science

Company

Press releases

Recent Posts

Yearly Archive

Tags

Applications

Products

About LUMICKS

For pricing, reach out to your application scientist or account manager

Fill in our contact form, we will reach out to you!

Join our newsletter

Download our webinar recording:

Download our Cell Therapy (CAR-T, TCR, NK) applications deck

Accept cookies for the best website experience